PAVmed Reports Q1 Revenue of $22 Million
Reports Q1 revenue $22,000 vs. $8,000 last year. PAVmed had cash and cash equivalents of $6.5M as of March 31, compared to $1.5M as of December 31, 2025. "PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy," said Lishan Aklog, PAVmed's Chairman and CEO. "Veris continues to expand its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission, and Lucid continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage. We are also actively advancing multiple technologies within our relaunched medical device portfolio under Joseph Virgilio's leadership, while increasingly leveraging his experience building and scaling growth-stage businesses."
